trial

ECT in Ultra-resistant Schizophrenia

NCTId NCT03542903
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 64 (estimated)
Sponsored by Centre Hospitalier du Rouvray
Primary completion 2023-10-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
64 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2018-07-04
Primary completion
2023-10-04
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
electroconvulsive therapy

Sponsors

Centre Hospitalier du RouvrayLead Sponsor
University Hospital, RouenCollaborator
University Hospital, BordeauxCollaborator
Nantes University HospitalCollaborator
University Hospital, ToulouseCollaborator
University Hospital, CaenCollaborator
Centre Hospitalier Henri LaboritCollaborator
Centre Hospitalier St AnneCollaborator
Centre Hospitalier de CadillacCollaborator
Hôpital Louis MourierCollaborator
University Hospital, MontpellierCollaborator
University Hospital, Clermont-FerrandCollaborator
Centre hospitalier de Ville-Evrard, FranceCollaborator

Sites

10 total
Bordeaux, FranceCadillac, FranceCaen, FranceClermont-Ferrand, FranceMontpellier, FranceNantes, FranceNeuilly-sur-Marne, FranceParis, FrancePoitiers, FranceToulouse, France

Facts & assertions

4 sourced
Enrollment
64
Phase
NA
Primary Completion Date
2023-10-04
Status
UNKNOWN
relationships
The graph out of here
drug
electroconvulsive therapy
drug
lead_sponsor
Centre Hospitalier du Rouvray
company
collaborator
University Hospital, Rouen
company
University Hospital, Bordeaux
company
indication
Schizophrenia
indication
Schizophrenia
indication
Electroconvulsive Therapy
indication